Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2007-03-12 13:20:14 UTC |
---|
Update Date | 2022-03-07 02:49:29 UTC |
---|
HMDB ID | HMDB0005814 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Testosterone enanthate |
---|
Description | Testosterone enanthate is used in androgen substitution to replace testosterone at levels as close to physiological levels as is possible. For some androgen-dependent functions testosterone is a pro-hormone, peripherally converted to 5alpha-dihydrotestosterone (DHT) and 17beta-estradiol (E2), of which the levels preferably should be within normal physiological ranges. Furthermore, androgens should have a good safety profile without adverse effects on the prostate, serum lipids, liver or respiratory function, and they must be convenient to use and patient-friendly, with a relative independence from medical services. Natural testosterone is viewed as the best androgen for substitution in hypogonadal men. testosterone enanthate is used to treat male hypogonadism. Male hypogonadism is one of the most common endocrinologic syndromes. The diagnosis is based on clinical signs and symptoms plus laboratory confirmation via the measurement of low morning testosterone levels on two different occasions. Serum luteinizing hormone and follicle-stimulating hormone levels distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. In primary hypogonadal men the on bone mineral density (BMD) responds dose dependently to testosterone substitution, whereas in secondary hypogonadism only testosterone enanthate treatment significantly increased the BMD. In all mammalian species studied to date, testosterone has been found to be the predominant intratesticular steroid. In volunteers receiving hormonal contraception by using a combination of testosterone enanthate and levonorgestrel, there is a profound reduction of both intratesticular testosterone concentration and androgen bioactivity. High doses of testosterone enanthate can normalize hematocrit values of maintenance hemodialysis patients with replenished bone marrow iron stores. testosterone enanthate is classified as a prohibited substance by the World Anti-Doping Agency (WADA) and its use may be detected by way of the urinary testosterone/epitestosterone (T/E) ratio. (PMID: 16185098 , 16467270 , 15329035 , 17530941 , 17484401 , 4028529 , 12792150 ). | Read more...
---|
Structure | [H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 |
---|
Synonyms | Value | Source |
---|
17-((1-Oxoheptyl)oxy)androst-4-en-3-one | ChEBI | 17-Hydroxyandrost-4-en-3-one, 17-heptanoate | ChEBI | 17beta-Hydroxyandrost-4-en-3-one heptanoate | ChEBI | Testosterone 17-enanthate | ChEBI | Testosterone heptanoate | ChEBI | Delatestryl | Kegg | 17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid | Generator | 17b-Hydroxyandrost-4-en-3-one heptanoate | Generator | 17b-Hydroxyandrost-4-en-3-one heptanoic acid | Generator | 17beta-Hydroxyandrost-4-en-3-one heptanoic acid | Generator | 17Β-hydroxyandrost-4-en-3-one heptanoate | Generator | 17Β-hydroxyandrost-4-en-3-one heptanoic acid | Generator | Testosterone 17-enanthic acid | Generator | Testosterone heptanoic acid | Generator | Testosterone enanthic acid | Generator | 17beta-Enanthoxyandrost-4-en-3-one | HMDB | 17beta-Hydroxyandrost-4-en-3-one enanthate | HMDB | 4-Androsten-17beta-ol-3-one 17-enanthate | HMDB | 4-Androsten-3-one 17beta-enanthate | HMDB | Androgyn l.a. | HMDB | Andropository | HMDB | Androtardyl | HMDB | Atlatest | HMDB | DEA no. 4000 | HMDB | Delatest | HMDB | DePatestrye | HMDB | depo-testro Med | HMDB | Ditate | HMDB | Durathate | HMDB | Everone | HMDB | Exten test | HMDB | Malogen l.a. | HMDB | Malogen l.a.200 | HMDB | Orquisteron-e | HMDB | Primotestone | HMDB | reposo TMD | HMDB | Testanthate | HMDB | Testate | HMDB | Testenate | HMDB | Testinon | HMDB | Testoenant | HMDB | Testonenant | HMDB | Testosterone 17beta-heptanoate | HMDB | Testosterone 17beta-heptanoic acid | HMDB | Testosterone enantate | HMDB | Testosterone heptoate | HMDB | Testosterone heptoic acid | HMDB | Testosterone heptylate | HMDB | Testosterone oenanthate | HMDB | Testostroval | HMDB | BTG Brand OF testosterone enanthate | MeSH, HMDB | Jenapharm brand OF testosterone enanthate | MeSH, HMDB | Rotexmedica brand OF testosterone enanthate | MeSH, HMDB | Testosteron-depot jenapharm | MeSH, HMDB | Pasadena brand OF testosterone enanthate | MeSH, HMDB | Primoteston depot | MeSH, HMDB | Rugby brand OF testosterone enanthate | MeSH, HMDB | Testosteron depot-rotexmedica | MeSH, HMDB | Testosteron-depot eifelfango | MeSH, HMDB | Testrin p.a. | MeSH, HMDB | Roberts brand OF testosterone enanthate | MeSH, HMDB | eifelfango Brand OF testosterone enanthate | MeSH, HMDB | Schering brand OF testosterone enanthate | MeSH, HMDB | Theramed brand OF testosterone enanthate | MeSH, HMDB | Theramex | MeSH, HMDB |
| Show more...
---|
Chemical Formula | C26H40O3 |
---|
Average Molecular Weight | 400.594 |
---|
Monoisotopic Molecular Weight | 400.297745146 |
---|
IUPAC Name | (1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl heptanoate |
---|
Traditional Name | everone |
---|
CAS Registry Number | 315-37-7 |
---|
SMILES | [H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 |
---|
InChI Key | VOCBWIIFXDYGNZ-IXKNJLPQSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as steroid esters. Steroid esters are compounds containing a steroid moiety which bears a carboxylic acid ester group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Steroid esters |
---|
Direct Parent | Steroid esters |
---|
Alternative Parents | |
---|
Substituents | - Steroid ester
- Androgen-skeleton
- Androstane-skeleton
- 3-oxosteroid
- 3-oxo-delta-4-steroid
- Oxosteroid
- Delta-4-steroid
- Cyclohexenone
- Ketone
- Carboxylic acid ester
- Cyclic ketone
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Organooxygen compound
- Carbonyl group
- Organic oxide
- Organic oxygen compound
- Hydrocarbon derivative
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 36 - 37.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Testosterone enanthate,1TMS,isomer #1 | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3CC[C@]12C | 3242.8 | Semi standard non polar | 33892256 | Testosterone enanthate,1TMS,isomer #1 | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3CC[C@]12C | 3195.3 | Standard non polar | 33892256 | Testosterone enanthate,1TMS,isomer #1 | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C)=CC[C@]4(C)[C@H]3CC[C@]12C | 3723.4 | Standard polar | 33892256 | Testosterone enanthate,1TBDMS,isomer #1 | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3CC[C@]12C | 3492.8 | Semi standard non polar | 33892256 | Testosterone enanthate,1TBDMS,isomer #1 | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3CC[C@]12C | 3398.7 | Standard non polar | 33892256 | Testosterone enanthate,1TBDMS,isomer #1 | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(O[Si](C)(C)C(C)(C)C)=CC[C@]4(C)[C@H]3CC[C@]12C | 3843.8 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone enanthate GC-MS (Non-derivatized) - 70eV, Positive | splash10-00dr-3479000000-622103246e9253c3578f | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone enanthate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Testosterone enanthate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 10V, Positive-QTOF | splash10-0udi-2594800000-2fe5b98ade2c6812e290 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 20V, Positive-QTOF | splash10-022i-5592000000-689f1cdb34f31cd98d15 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 40V, Positive-QTOF | splash10-05mo-4490000000-d66a654ef39db2b12265 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 10V, Negative-QTOF | splash10-0002-0149000000-2bec5293e6f91f7dbff5 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 20V, Negative-QTOF | splash10-000i-0393000000-1dfe91f6ac9835af8928 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 40V, Negative-QTOF | splash10-0a4r-2190000000-387672165ae5773ca45b | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 10V, Negative-QTOF | splash10-0002-0109000000-867f88cb280a910aabe9 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 20V, Negative-QTOF | splash10-01r2-1926000000-bc6e667c95b200d2ea91 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 40V, Negative-QTOF | splash10-0a4l-9101000000-86eb2f6d2ad8f02878cd | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 10V, Positive-QTOF | splash10-0udi-0040900000-fe6a5cf79e52e56acc46 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 20V, Positive-QTOF | splash10-0229-1981100000-256658d507dc1dea4517 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Testosterone enanthate 40V, Positive-QTOF | splash10-06r6-5920000000-9787c0613d8215ab200b | 2021-09-25 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DBSALT001030 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023772 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 9045 |
---|
KEGG Compound ID | C08157 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Testosterone enanthate |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 9416 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 9464 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Ulrich, Miroslav; Novacek, Alois; Stejskal, Frantisek. Testosterone enanthate. (1960), CS 95825 19600615 CAN 55:81895 AN 1961:81895 |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Jarow JP, Zirkin BR: The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci. 2005 Dec;1061:208-20. [PubMed:16467270 ]
- Darby E, Anawalt BD: Male hypogonadism : an update on diagnosis and treatment. Treat Endocrinol. 2005;4(5):293-309. [PubMed:16185098 ]
- Gooren LJ, Bunck MC: Androgen replacement therapy: present and future. Drugs. 2004;64(17):1861-91. [PubMed:15329035 ]
- Rogerson S, Weatherby RP, Deakin GB, Meir RA, Coutts RA, Zhou S, Marshall-Gradisnik SM: The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men. J Strength Cond Res. 2007 May;21(2):354-61. [PubMed:17530941 ]
- Giuberti A, Manganini V, Picozzi SC, Vigano P, Strada GR: Complete genital prosthetization in patients treated with bilateral orchiectomy for metachronous testicular cancer. Arch Ital Urol Androl. 2007 Mar;79(1):26-9. [PubMed:17484401 ]
- Schustack A, Meshiaj D, Waiss Z, Gotloib L: Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow-up of up to 8 years on 16 patients. Clin Nephrol. 1985 Jun;23(6):303-6. [PubMed:4028529 ]
- Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F: Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res. 2003;60(1):21-8. [PubMed:12792150 ]
|
---|